Drug makers losing a bid to foil generic painkillers
The New York Times, January 2, 2013
In coming months, generic drug producers are expected to introduce cheaper versions of OxyContin and Opana, two long-acting narcotic painkillers, or opioids, that are widely abused. But in hopes of delaying the move to generics, the makers of the brand name drugs, Purdue Pharma and Endo Pharmaceuticals, have introduced versions that are more resistant to crushing or melting, techniques abusers use to release the pills' narcotic payloads. The two drug makers, which say they are motivated not by profit but by public safety, have also been waging a multifront political and legal war to block sales of generics that are not tamper-resistant.
Most Viewed
Most Emailed
- How Medical Debt Forgiveness Benefits Hospitals
- Leapfrog Hospital Safety Scores 'Depressing'
- Patient Harm Data to Remain on Medicare's Hospital Compare Site
- Quiet ORs Better for Patient Safety
- Tavenner Confirmed as CMS Administrator
- Healthcare Leaders Sound Off on Organized Labor
- Building a Better Healthcare Board
- Esther Dyson's Population Health Dream
- CMS Seeks to 'Rapidly Reduce' Medicare Spending with $1B in Grants
- Rural Healthcare Can Entice the Best and Brightest
